Clinical trial
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in…
NCT02847637 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02847637 |
|---|---|
| Title | A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors |
| Official title | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors |
| Acronym | HAVEN 3 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Chugai Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Emicizumab, Factor VIII (FVIII) |
| Enrollment | 152 |
| Start date | Sep 27, 2016 |
| Primary completion | Sep 15, 2017 |
| Completion | May 12, 2022 |
| First posted | Jul 28, 2016 |
| Last update posted | Nov 16, 2022 |
| Countries | Australia, Costa Rica, France, Germany, Ireland, Italy, Japan, Poland, South Africa, South Korea, Spain, Taiwan and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: